2-bromoethyl-1-ethoxyethyl ether | 78487-70-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromoethyl-1-ethoxyethyl ether
• 英文别名: 1-bromo-2-(ethoxy-1-ethoxy)ethane；1-(2-Bromoethoxy)-1-ethoxyethane
• CAS: 78487-70-4
• 化学式: C₆H₁₃BrO₂
• 分子量: 197.072
• InChiKey: VEMBMVKAMZZYLP-UHFFFAOYSA-N

物化性质

• 沸点：
  63-64 °C(Press: 10 Torr)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromoethyl-1-ethoxyethyl ether 在 氢氧化钾 、 叔丁基锂 作用下， 反应 1.0h， 生成 2-(1-ethoxyethoxy)dec-1-en-3-ol
  参考文献：
  名称：

  环状乙烯基醚碳负离子—II：羰基化合物的制备及其应用

  摘要：

  描述了各种环状乙烯基醚的金属化条件以及所得碳负离子与亲电子试剂的反应条件。讨论了乙烯基醚结构对相对金属化速率的影响。介绍了该方法在各种类型羰基化合物的构建中的应用。

  DOI：

  10.1016/s0040-4020(01)93274-0
• 作为产物：
  描述：

  乙烯基乙醚 、 2-溴乙醇 在 4-甲基苯磺酸吡啶 作用下， 生成 2-bromoethyl-1-ethoxyethyl ether
  参考文献：
  名称：

  （-）-吲哚并立核苷239AB [（3R，5S，8aR）-3-butyl-5-（3-hydroxypropyl）-octahydroindolizine]的对映选择性合成。

  摘要：

  吲哚并立啶生物碱239AB的高度对映选择性合成是通过非对映选择性还原由（S）-邻苯二甲酸制备的手性环状β-烯胺酯来描述的。

  DOI：

  10.1016/0957-4166(96)00273-x

文献信息

• [EN] PYRIMIDINE AMIDE COMPOUNDS<br/>[FR] COMPOSÉS PYRIMIDINE AMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012123467A1

  公开（公告）日：2012-09-20

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的化合物为式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，例如哮喘和慢性阻塞性肺病（COPD）等，具有实用性。
• Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof
  申请人：Sumika Fine Chemicals Co., Ltd.

  公开号：US20040162340A1

  公开（公告）日：2004-08-19

  The present invention provides a method for producing compound (XIV) useful as an intermediate for pharmaceutical agents efficiently and economically on an industrial scale without using ozone oxidation and highly toxic reagent, and an intermediate used for this method. Particularly, the present invention provides a method for producing a compound having an absolute configuration represented by the formula (XV) and an enantiomer thereof without using a technique such as optical resolution and the like, and an intermediate used for this method. (1) Compound (XIII) as a starting material is led to compound (I), and after introducing a protecting group, subjected to reduction and cyclization to give compound (XIV). Particularly, compound (XIII) as a material is led to compound (I) via compound (XX) to produce compound (XIV). Using an optically active compound (XIII) as a starting material, a compound having an absolute configuration represented by the formula (XV) and the like are produced highly stereoselectively. (2) Compound (XXI) as a starting material is stereoselectively reduced to give compound (XXII), and by introduction of a protecting group, reduction and cyclization, compound (XXVI) is obtained, and by inverting hydroxyl group, compound (XV) is produced. 1 wherein each symbol is as defined in the specification.

  本发明提供了一种在工业规模上高效且经济地生产化合物(XIV)的方法，该化合物可作为制药中间体，无需使用臭氧氧化和高毒性试剂，以及用于该方法的中间体。特别是，本发明提供了一种生产具有由公式(XV)表示的绝对构型及其对映体的化合物的方法，无需使用光学分辨等技术，以及用于该方法的中间体。(1) 以化合物(XIII)为起始材料，引导至化合物(I)，引入保护基团后，进行还原和环化以得到化合物(XIV)。特别是，化合物(XIII)作为原料通过化合物(XX)引导至化合物(I)，以生产化合物(XIV)。使用具有光学活性的化合物(XIII)作为起始材料，高度立体选择性地生产具有由公式(XV)表示的绝对构型等的化合物。(2) 以化合物(XXI)为起始材料，立体选择性地还原得到化合物(XXII)，通过引入保护基团、还原和环化，得到化合物(XXVI)，并通过反转羟基，生产化合物(XV)。其中每个符号的定义如说明书中所述。
• Dilithiated 2-(Chloromethyl)-3-tosylpropene: A New γ-Chlorinated Allyl Sulfone Dianion in Organic Synthesis
  作者：Carmen Nájera、José M. Sansano

  DOI：10.1016/s0040-4020(01)87028-9

  日期：1994.3

  affords the allylic dianion 2 which reacts with deuterium oxide or very reactive alkylating agents to give α,α-disubstituted products 3 or 4, respectively. Monoalkylation at the α-position followed by cyclopropanation reaction takes place with n-alkyl bromides to provide tosylated methylenecyclopropanes 5. The reaction of dianion 2 with aldehydes or electrophilic olefins occurs at the α-position followed

  在DMPU存在下，于-90°C，在正丁基锂下，将2-（氯甲基）-3-甲苯磺酰基丙烯（1）与正丁基锂二甲酸酯化，生成烯丙基二价阴离子2，该二烯丙基二价阴离子与氘化氢或反应性强的烷基化剂反应生成α，α-二取代产品3或4。在α位进行单烷基化，然后与正烷基溴化物进行环丙烷化反应，以提供甲苯磺酸化的亚甲基环丙烷5。二价阴离子2与醛或亲电烯烃的反应发生在α位，然后进行相应的环合工艺，从而得到甲苯磺酸化的2,5-二氢呋喃6或环戊烯8， 分别。当使用酮作为亲电子试剂时，二价阴离子2在γ位反应生成3-（甲苯磺酰基亚甲基）四氢呋喃7。还研究了用汞齐钠或碘化sa（II）将化合物5-8还原脱磺酰化，得到相应的脱磺酰化衍生物22-26。
• Basic compound, resist composition and patterning process
  申请人：Watanabe Takeru

  公开号：US20050008968A1

  公开（公告）日：2005-01-13

  Resist compositions comprising basic compounds having a benzimidazole skeleton and a polar functional group have an excellent resolution and an excellent focus margin and are useful in microfabrication using electron beams or deep-UV light.

  含有苯并咪唑骨架和极性功能基团的碱性化合物抗蚀组合物具有优异的分辨率和优异的焦点余量，适用于使用电子束或深紫外光微加工。
• PROCESS FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE, INTERMEDIATE THEREOF AND PROCESS FOR PRODUCING THE SAME
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1589018A1

  公开（公告）日：2005-10-26

  The present invention provides a method for producing compound (XIV) useful as an intermediate for pharmaceutical agents efficiently and economically on an industrial scale without using ozone oxidation and highly toxic reagent, and an intermediate used for this method. Particularly, the present invention provides a method for producing a compound having an absolute configuration represented by the formula (XV) and an enantiomer thereof without using a technique such as optical resolution and the like, and an intermediate used for this method. (1) Compound (XIII) as a starting material is led to compound (I), and after introducing a protecting group, subjected to reduction and cyclization to give compound (XIV). Particularly, compound (XIII) as a material is led to compound (I) via compound (XX) to produce compound (XIV). Using an optically active compound (XIII) as a starting material, a compound having an absolute configuration represented by the formula (XV) and the like are produced highly stereoselectively. (2) Compound (XXI) as a starting material is stereoselectively reduced to give compound (XXII), and by introduction of a protecting group, reduction and cyclization, compound (XXVI) is obtained, and by inverting hydroxyl group, compound (XV) is produced. wherein each symbol is as defined in the specification.

  本发明提供了一种不使用臭氧氧化和剧毒试剂，在工业规模上高效、经济地生产用作药剂中间体的化合物(XIV)的方法，以及用于该方法的中间体。特别是，本发明提供了一种不使用光学解析等技术生产具有式（XV）代表的绝对构型的化合物及其对映体的方法，以及用于该方法的中间体。 (1) 将作为起始原料的化合物 (XIII) 转化为化合物 (I)，并在引入保护基团后进行还原和环化反应，得到化合物 (XIV)。特别是，将化合物（XIII）作为原料，通过化合物（XX）引向化合物（I），生成化合物（XIV）。以光学活性化合物 (XIII) 为起始原料，可高度立体选择性地制备出绝对构型如式 (XV) 所示的化合物等。 (2) 以化合物（XXI）为起始原料，进行立体选择性还原，得到化合物（XXII），通过引入保护基、还原和环化，得到化合物（XXVI），通过反转羟基，得到化合物（XV）。 其中各符号如说明书中所定义。